Literature DB >> 3826895

Idiopathic pulmonary fibrosis. Pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy.

L C Watters, M I Schwarz, R M Cherniack, J A Waldron, T L Dunn, R E Stanford, T E King.   

Abstract

Analysis of bronchoalveolar lavage cellular constituents has been recommended as a valuable method for the characterization of the inflammatory cellular population and for studying cellular interactions in the lower respiratory tract of patients with idiopathic pulmonary fibrosis (IPF). However, the clinical relevance of the enumeration of cells in bronchoalveolar lavage fluid (BALF) from patients with IPF remains controversial. We therefore examined the correlations between BALF cellular constituents and both the histopathologic abnormalities and the subsequent clinical response to corticosteroid therapy in 26 newly diagnosed, untreated patients with IPF. The BALF lymphocytosis was associated with moderate-to-severe alveolar septal inflammation (p less than 0.0005) and with a relative lack of histologic honeycombing (p less than 0.05). On the other hand, BALF neutrophil and eosinophil contents did not significantly correlate with any of eleven particular histopathologic abnormalities, and BALF neutrophil and lymphocyte contents did not correlate with the degree of clinical impairment (quantitated by a composite score based on dyspnea, radiographic abnormalities, and physiologic impairment) upon presentation. However, BALF eosinophil content correlated significantly with the severity of clinical impairment, higher eosinophil counts being associated with more severe initial clinical impairment (p less than 0.01). Neither pretreatment BALF neutrophil nor eosinophil content was related to the frequency or magnitude of subsequent clinical change in 20 patients evaluated before and after 1 yr of corticosteroid therapy. In contrast, pretreatment BALF lymphocytosis was associated with significant subsequent clinical improvement (p less than 0.002).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3826895     DOI: 10.1164/arrd.1987.135.3.696

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  41 in total

Review 1.  Clinical usefulness of high resolution computed tomography in cryptogenic fibrosing alveolitis.

Authors:  A Wells
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

Review 2.  The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction.

Authors: 
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

Review 3.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  Bronchoalveolar lavage as a research tool.

Authors:  E H Walters; P V Gardiner
Journal:  Thorax       Date:  1991-09       Impact factor: 9.139

5.  Definition of a lipopolysaccharide-responsive element in the 5'-flanking regions of MuRantes and crg-2.

Authors:  H S Shin; B E Drysdale; M L Shin; P W Noble; S N Fisher; W A Paznekas
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

6.  Release of PGE2 and IL-1 as related to suppressive activity of alveolar macrophages from interstitial lung diseases.

Authors:  E Fireman; S Ben-Efraim; M Topilsky
Journal:  Agents Actions       Date:  1989-01

Review 7.  Interstitial lung disease: the diagnostic role of bronchoscopy.

Authors:  Jad Kebbe; Tony Abdo
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

8.  Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts.

Authors:  D W Mapel; W C Hunt; R Utton; K B Baumgartner; J M Samet; D B Coultas
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

9.  Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis.

Authors:  M A Johnson; S Kwan; N J Snell; A J Nunn; J H Darbyshire; M Turner-Warwick
Journal:  Thorax       Date:  1989-04       Impact factor: 9.139

10.  Correlation between pulmonary fibrosis and the lung pressure-volume curve.

Authors:  R H Sansores; A Ramirez-Venegas; R Pérez-Padilla; M Montaño; C Ramos; C Becerril; M Gaxiola; P Paré; M Selman
Journal:  Lung       Date:  1996       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.